The Trump administration, led by Health and Human Services Secretary Robert F. Kennedy Jr., has begun reducing federal funding for harm-reduction initiatives, including needle exchanges and drug-testing strips. These cuts follow a July executive order directing federal agencies to defund programs focused on safe consumption. Secretary Kennedy stated that harm-reduction efforts lead to "open-air drug markets" and argued that the approach is ineffective, favoring instead abstinence-based recovery programs and religious support networks.
Despite the federal shift, several Republican-led states are moving to maintain or expand these programs. Florida Governor Ron DeSantis recently signed legislation legalizing xylazine test strips, and Indiana lawmakers extended the state's syringe service program through 2031. In Ohio, Governor Mike DeWine authorized emergency rules to expand access to fentanyl and xylazine testing kits, citing their role in reducing overdose risks. Additionally, Kentucky’s attorney general allocated $34 million in opioid settlement funds to addiction nonprofits, including those utilizing harm-reduction strategies.
The policy disagreement arrives as national overdose deaths have dropped from a peak of 105,000 in 2023 to under 70,000. Public health advocates and some state GOP lawmakers attribute this decline partly to the availability of testing tools and clean needles, which aim to prevent infections and fatal poisonings. Critics of these programs, including administration officials and some conservative analysts, argue that there is insufficient evidence that such tools facilitate long-term recovery and express concerns over community safety.